These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7320182)

  • 1. Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
    Powis G
    J Chromatogr; 1981 Dec; 226(2):514-20. PubMed ID: 7320182
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
    Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
    Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
    Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
    Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
    Powis G; Kovach JS
    Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes.
    Murdock KC; Child RG; Lin Y; Warren JD; Fabio PF; Lee VJ; Izzo PT; Lang SA; Angier RB; Citarella RV; Wallace RE; Durr FE
    J Med Chem; 1982 May; 25(5):505-18. PubMed ID: 6806475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.
    Savaraj N; Lu K; Valdivieso M; Burgess M; Umsawasdi T; Benjamin RS; Loo TL
    Clin Pharmacol Ther; 1982 Mar; 31(3):312-6. PubMed ID: 7060314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (Cl 216,942).
    Bowden GT; Garcia D; Peng YM; Alberts DS
    Cancer Res; 1982 Jul; 42(7):2660-5. PubMed ID: 7083158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma.
    Rubin J; Kvols LK; Moertel CG; Jones AR; Hahn RG; O'Connell MJ
    Am J Clin Oncol; 1983 Aug; 6(4):477-9. PubMed ID: 6869319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
    Von Hoff DD; Myers JW; Kuhn J; Sandbach JF; Pocelinko R; Clark G; Coltman CA
    Cancer Res; 1981 Aug; 41(8):3118-21. PubMed ID: 6265075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride.
    Tseng MT; Safa AR
    Cancer Res; 1983 Dec; 43(12 Pt 1):5910-4. PubMed ID: 6640539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of 4,5-dihydro-6-[4-(1H-imidazol-1-yl) phenyl]-3(2H)-pyridazinone hydrochloride, a new cardiotonic, in plasma and urine by reversed-phase high-performance liquid chromatography.
    Hayes AG; Mehta S; Chang T
    J Chromatogr; 1984 Dec; 336(2):446-51. PubMed ID: 6530478
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical analysis for the anti-neoplastic agent 1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)-amino)9,10-anthracenedio ne dihydrochloride (NSC 301739) in plasma. Application of temperature control to provide selectivity in paired-ion high-performance liquid chromatography.
    Reynolds DL; Sternson LA; Repta AJ
    J Chromatogr; 1981 Feb; 222(2):225-40. PubMed ID: 7251740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the antiallergenic agent, N-[4-(1H-imidazol-1-yl)butyl]-2-(1-methylethyl)-11-oxo-11H- pyrido [2,1-b]quinazoline-8-carboxamide, in plasma by reversed-phase high-performance liquid chromatographic analysis using fluorometric detection.
    Strojny N; Puglisi CV; de Silva JA
    J Chromatogr; 1984 Dec; 336(2):301-11. PubMed ID: 6530462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
    Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
    Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
    Wang BS; Lumanglas AL; Ruszala-Mallon VM; Durr FE
    Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-performance liquid chromatographic determination of 6-amidino-2-naphthyl [4-(4,5-dihydro-1H-imidazol-2-yl) amino]benzoate dimethanesulphonate and its metabolites in biological fluids.
    Marunaka T; Maniwa M; Matsushima E; Yoshida K; Azuma R; Kurotori M; Komatsu S
    J Chromatogr; 1988 Dec; 433():177-86. PubMed ID: 3266216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.
    Pillon L; Moore MJ; Thiessen JJ
    Ther Drug Monit; 1994 Apr; 16(2):186-90. PubMed ID: 8009568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Leads for phase II trials in man.
    Von Hoff DD; Coltman CA; Forseth B
    Cancer Chemother Pharmacol; 1981; 6(2):141-4. PubMed ID: 7307232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.